Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. develops clinical-stage biopharmaceutical therapies for metabolic and endocrine disorders. News about VKTX centers on VK2735, a dual GLP-1 and GIP receptor agonist being developed in subcutaneous and oral formulations for obesity and other metabolic disorders, including updates from the VANQUISH and VENTURE clinical programs.
Recurring company updates also cover financial results, corporate development, investor-conference participation, and earlier pipeline work such as an amylin agonist program. Viking's announcements typically connect clinical trial design, efficacy and safety data, regulatory interactions, and cash resources to the progress of its metabolic-disease portfolio.
Viking Therapeutics (NASDAQ: VKTX) will announce its fourth quarter and year-end 2022 financial results on February 8, 2023, after market close. A conference call to discuss the results will follow at 4:30 p.m. ET. The company focuses on developing therapies for metabolic and endocrine disorders and is currently running clinical trials for its compounds VK2809, VK2735, and VK0214. VK2809 is in a Phase 2b study for treating NASH and fibrosis, showing promising results in earlier trials. Interested parties can participate in the call by dialing specified numbers or can access the webcast on Viking's website.
Viking Therapeutics (NASDAQ: VKTX) announced the completion of patient enrollment in its Phase 2b clinical trial for VK2809, a novel treatment for biopsy-confirmed non-alcoholic steatohepatitis (NASH). This double-blind, placebo-controlled trial targets a primary endpoint evaluating liver fat content changes at 12 weeks. The study represents a significant advancement in developing therapies for NASH. Viking previously achieved promising results in a Phase 2a trial, demonstrating reductions in liver fat and plasma lipids. Data for the primary endpoint is expected in the first half of 2023.
Viking Therapeutics, Inc. (VKTX) announced that CEO Brian Lian, Ph.D., will present at the Stifel 2022 Healthcare Conference on November 15-16, 2022, in New York City. The presentation is scheduled for 3:35 p.m. Eastern on November 15, and will include a live webcast available on their website. Viking focuses on developing novel therapies for metabolic and endocrine disorders, with ongoing clinical programs including VK2809 for non-alcoholic steatohepatitis and VK2735 for various metabolic disorders.
Viking Therapeutics (VKTX) announced its Q3 2022 financial results, reporting a net loss of $15.8 million, or $0.21 per share, compared to $13.2 million, or $0.17 per share, in Q3 2021. The company ended the quarter with $155 million in cash, supporting ongoing clinical trials for VK2809, VK2735, and VK0214, with data expected in 2023. The Phase 2b VOYAGE study for VK2809 is on track for Q4 2022 enrollment completion. Increased R&D and G&A expenses were noted, affecting the overall financial performance.
Viking Therapeutics (NASDAQ: VKTX) announced the release of its third-quarter 2022 financial results on October 26, 2022, after market close. A conference call will be held on the same day at 4:30 p.m. Eastern Time to discuss these results and provide corporate updates. The company's pipeline includes VK2809, in Phase 2b for NASH, and VK2735, in Phase 1 for metabolic disorders, showcasing ongoing innovation in therapies targeting metabolic and endocrine conditions.
Viking Therapeutics, Inc. (NASDAQ: VKTX) announced its participation in two investor conferences from September 12-14, 2022. At the H.C. Wainwright 24th Annual Global Investment Conference, Dr. Lian will deliver a presentation on September 14 at 12:30 PM Eastern, with a hybrid format available. Additionally, Viking management will engage in 1-on-1 meetings at the Morgan Stanley 20th Annual Global Healthcare Conference during the same dates, held at the Sheraton New York Hotel. Webcasts of the presentations will be accessible via the Viking Therapeutics website.
Viking Therapeutics, Inc. (NASDAQ: VKTX) announced that CEO Brian Lian, Ph.D., will participate in a fireside chat at the BTIG Biotechnology Conference 2022 on August 8-9, 2022. The event will be a hybrid format, facilitating both in-person and virtual attendance. Viking focuses on developing innovative therapies for metabolic and endocrine disorders, including its clinical programs VK2809, VK2735, and VK0214. VK2809 is currently in a Phase 2b study for non-alcoholic steatohepatitis, showing promising results for lipid and metabolic disorders.
Viking Therapeutics (NASDAQ: VKTX) reported Q2 2022 financial results, showing a net loss of $17.4 million, or $0.23 per share, compared to a loss of $15.4 million in Q2 2021. With $169 million in cash, the company is positioned to advance its clinical programs. Key updates include the VOYAGE Phase 2b study for VK2809, expected to complete enrollment in Q4 2022, and initial results from the Phase 1 study of VK2735 anticipated by year-end. Following FDA clearance, dosing for VK0214 in X-ALD patients is set to resume, with enrollment completion expected in H1 2023.
Viking Therapeutics (NASDAQ: VKTX) announced it will release its second quarter 2022 financial results on July 27, 2022, after market close. A conference call discussing these results and corporate updates is scheduled for 4:30 p.m. Eastern Time on the same day. Interested parties can join the call by dialing (844) 850-0543 from the U.S. or (412) 317-5199 internationally. For more details on the company's clinical programs, including VK2809 and VK2735, which target metabolic and endocrine disorders, visit www.vikingtherapeutics.com.
Viking Therapeutics (VKTX) announced the FDA has lifted the clinical hold on its Phase 1b trial for VK0214, aimed at treating X-linked adrenoleukodystrophy (X-ALD). The hold was lifted after an in vivo genotoxicity study showed no adverse effects. Enrollment for the trial will resume shortly. VK0214, a thyroid hormone beta receptor agonist, has achieved orphan drug designation and previously demonstrated encouraging safety and efficacy in earlier trials. The Phase 1b study targets patients with the AMN form of X-ALD, with primary objectives focused on safety and tolerability.